arrow
返回
M

Michael D. Kaufman

swiss institute experimental cancer research

36H指数
158论文数
5.5K被引数
收录论文 30
发表时间
Process Development and GMP Production of a Conjugate Warhead: Auristatin F-HPA-Ala/TFA (XMT-1864/TFA)
err2022-02-15
err2
PREAI
errConlon, Patrick R.; Gurijala, Venu Reddy; Kaufman, Michael; Li, Dachang; Li, Jiuyuan; Li, Yuanyuan; Yin, Mao; Reddy, Bollu Satyanarayan; Wagler, Thomas; Wang, Zedong; Xu, Zhongmin; Yurkovetskiy, Aleksandr V.; Zhu, Lei
err分享
err收藏
Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages
err2021-08-25
err37
errOAAI
errSmith, Bryan D.; Kaufman, Michael D.; Wise, Scott C.; Ahn, Yu Mi; Caldwell, Timothy M.; Leary, Cynthia B.; Lu, Wei-Ping; Tan, Gege; Vogeti, Lakshminarayana; Vogeti, Subha; Wilky, Breelyn A.; Davis, Lara E.; Sharma, Maitreyi; Ruiz-Soto, Rodrigo; Flynn, Daniel L.
err分享
err收藏
A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer
err2020-02-06
err77
errOAAI
errSullivan, Ryan J.; Hollebecque, Antoine; Flaherty, Keith T.; Shapiro, Geoffrey I.; Ahnert, Jordi Rodon; Millward, Michael J.; Zhang, Wei; Gao, Ling; Sykes, Amanda; Willard, Melinda D.; Yu, Danni; Schade, Andrew E.; Crowe, KrisAnne; Flynn, Daniel L.; Kaufman, Michael D.; Henry, James R.; Peng, Sheng-Bin; Benhadji, Karim A.; Conti, Ilaria; Gordon, Michael S.; Tiu, Ramon V.; Hong, David S.
err分享
err收藏
Inhibition of oncogenic and drug-resistant PDGFRA and KIT alterations by DCC-2618
err2018-07-01
err0
PREAI
errSmith, Bryan D.; Kaufman, Michael D.; Gupta, Anu; Leary, Cynthia B.; Lu, Wei-ping; Bulfer, Stacie L.; Al-Ani, Gada; Singh, Jarnail; Vogeti, Subha; Heinrich, Michael C.; Flynn, Daniel L.
err分享
err收藏
The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors
err2017-11-01
err112
errOAAI
errHarney, Allison S.; Karagiannis, George S.; Pignatelli, Jeanine; Smith, Bryan D.; Kadioglu, Ece; Wise, Scott C.; Hood, Molly M.; Kaufman, Michael D.; Leary, Cynthia B.; Lu, Wei-Ping; Al-Ani, Gada; Chen, Xiaoming; Entenberg, David; Oktay, Maja H.; Wang, Yarong; Chun, Lawrence; De Palma, Michele; Jones, Joan G.; Flynn, Daniel L.; Condeelis, John S.
err分享
err收藏
Translational research in a phase I proof-of-concept study supports that DCC-2618 is a pan-KIT inhibitor
err2017-07-01
err0
PREAI
errJanku, Filip; Razak, Albi; Gordon, Michael; Brooks, David; Flynn, Daniel; Gupta, Anu; Kaufman, Michael; Leary, Cynthia; Smith, Bryan; Westwood, Deb; Somaiah, Neeta; Helman, Elena; Gerstenberger, Eric; Rosen, Oliver; George, Suzanne
err分享
err收藏
DCC-2618, a pan KIT and PDGFR switch control inhibitor, achieves proof-of-concept in a first-in-human study
err2016-12-01
err3
PREAI
errJanku, F.; George, S.; Razak, A.; Gordon, M.; Brooks, D.; Flynn, D. G.; Kaufman, M.; Pitman, J.; Smith, B.; Somaiah, N.; Gerstenberger, E.; Westwood, D.; Rosen, O.
err分享
err收藏
The highly specific CSF1R inhibitor DCC-3014 exhibits immunomodulatory and anti-invasive activities in cancer models
err2016-07-15
err8
PREAI
errSmith, Bryan D.; Leary, Cynthia B.; Lu, Wei-Ping; Kaufman, Michael D.; Flynn, Daniel L.
err分享
err收藏
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
err2015-10-08
err221
errOAAI
errKappos, L.; Wiendl, H.; Selmaj, K.; Arnold, D. L.; Havrdova, E.; Boyko, A.; Kaufman, M.; Rose, J.; Greenberg, S.; Sweetser, M.; Riester, K.; O'Neill, G.; Elkins, J.
err分享
err收藏
Daclizumab HYP reduces total disability burden of patients with multiple sclerosis: results from an exploratory area under the curve analysis
err2015-10-01
err0
errOAAI
errBoyko, A.; Kappos, L.; Rose, J.; Selmaj, K.; Arnold, D. L.; Havrdova, E.; Kaufman, M.; Wiendl, H.; Greenberg, S.; Shang, S.; Wang, P.; Barbato, L.
err分享
err收藏
Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2
err2015-09-02
err63
errOAAI
errSmith, Bryan D.; Kaufman, Michael D.; Leary, Cynthia B.; Turner, Benjamin A.; Wise, Scott C.; Ahn, Yu Mi; Booth, R. John; Caldwell, Timothy M.; Ensinger, Carol L.; Hood, Molly M.; Lu, Wei-Ping; Patt, Tristan W.; Patt, William C.; Rutkoski, Thomas J.; Samarakoon, Thiwanka; Telikepalli, Hanumaiah; Vogeti, Lakshminarayana; Vogeti, Subha; Yates, Karen M.; Chun, Lawrence; Stewart, Lance J.; Clare, Michael; Flynn, Daniel L.
err分享
err收藏
Altiratinib is a potent inhibitor of TRK kinases and is efficacious in TRK-fusion driven cancer models
err2015-08-01
err6
PREAI
errSmith, Bryan D.; Leary, Cynthia B.; Turner, Benjamin A.; Kaufman, Michael D.; Wise, Scott C.; Garcia-Rendueles, Maria E. R.; Fagin, James A.; Flynn, Daniel L.
err分享
err收藏
DCC-2618 is a potent inhibitor of wild-type and mutant KIT, including refractory Exon 17 D816 KIT mutations, and exhibits efficacy in refractory GIST and AML xenograft models
err2015-08-01
err12
PREAI
errSmith, Bryan D.; Hood, Molly M.; Wise, Scott C.; Kaufman, Michael D.; Lu, Wei-Ping; Rutkoski, Thomas; Flynn, Daniel L.; Heinrich, Michael C.
err分享
err收藏
Discovery of 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against BRAF or RAS Mutant Tumor Cells
err2015-05-12
err85
errOAAI
errHenry, James R.; Kaufman, Michael D.; Peng, Sheng-Bin; Ahn, Yu Mi; Caldwell, Timothy M.; Vogeti, Lakshminarayana; Telikepalli, Hanumaiah; Lu, Wei-Ping; Hood, Molly M.; Rutkoski, Thomas J.; Smith, Bryan D.; Vogeti, Subha; Miller, David; Wise, Scott C.; Chun, Lawrence; Zhang, Xiaoyi; Zhang, Youyan; Kays, Lisa; Hipskind, Philip A.; Wrobleski, Aaron D.; Lobb, Karen L.; Clay, Julia M.; Cohen, Jeffrey D.; Walgren, Jennie L.; McCann, Denis; Patel, Phenil; Clawson, David K.; Guo, Sherry; Manglicmot, Danalyn; Groshong, Chris; Logan, Cheyenne; Starling, James J.; Flynn, Daniel L.
err分享
err收藏
Rebastinib, a selective TIE2 kinase inhibitor, decreases TIE2-expressing macrophages, reduces metastasis, and increases survival in murine cancer models
err2015-01-12
err0
PREAI
errFlynn, Daniel L.; Kaufman, Michael D.; Leary, Cynthia B.; Hood, Molly M.; Lu, Wei-Ping; Turner, Benjamin A.; Wise, Scott C.; Rudoltz, Marc S.; Smith, Bryan D.
err分享
err收藏
The specific FMS kinase inhibitor, DCC-3014, durably inhibits FMS kinase in vivo and blocks cancer bone invasiveness
err2015-01-12
err6
PREAI
errSmith, Bryan D.; Kaufman, Michael D.; Leary, Cynthia B.; Hood, Molly M.; Lu, Wei-Ping; Turner, Benjamin A.; Vogeti, Subha; Wise, Scott C.; Flynn, Daniel L.
err分享
err收藏
Altiratinib (DCC-2701): a balanced inhibitor of MET, TIE2, and VEGFR2 kinases that exhibits broad anti-tumor and anti-angiogenic activities
err2014-11-01
err0
PREAI
errFlynn, D.; Smith, B. D.; Leary, C. B.; Kaufman, M. D.; Turner, B. A.; Hood, M. M.; Lu, W. P.; Rutkoski, T. J.; Samarakoon, T.; Vogeti, S.; Wise, S. C.; Rosen, O.
err分享
err收藏
Identification of LY3009120 as a pan inhibitor of Raf isoforms and dimers with minimal paradoxical activation and activities against BRaf or Ras mutant tumor cells
err2014-10-01
err2
PREAI
errPeng, Sheng-Bin; Henry, James; Kaufman, Michael; Lu, Wei-Ping; Smith, Bryan D.; Vogeti, Subha; Wise, Scott; Zhang, Youyan; Van Horn, Robert; Zhang, Xiaoyi; Yin, Tinggui; Yadav, Vipin; Huber, Lysiane; Kays, Lisa; Walgren, Jennie; McCann, Denis; Patel, Phenil; Buchanan, Sean; Conti, Ilaria; Starling, James J.; Flynn, Daniel L.
err分享
err收藏
Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis
err2014-06-01
err69
PREAI
errKaufman, Michael; Pardo, Gabriel; Rossman, Howard; Sweetser, Marianne T.; Forrestal, Fiona; Duda, Petra
err分享
err收藏
Rebastinib, a small molecule TIE2 kinase inhibitor, prevents primary tumor growth and lung metastasis in the PyMT breast cancer model
err2014-05-01
err1
PREAI
errSmith, Bryan D.; Hood, Molly M.; Kaufman, Michael D.; Berger, Mark; Flynn, Daniel L.; Wise, Scott C.
err分享
err收藏